ClinVar Miner

Submissions for variant NM_001360016.2(G6PD):c.769C>G (p.Arg257Gly)

dbSNP: rs2070375134
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 2
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Labcorp Genetics (formerly Invitae), Labcorp RCV001348562 SCV001542869 uncertain significance Anemia, nonspherocytic hemolytic, due to G6PD deficiency 2020-09-15 criteria provided, single submitter clinical testing Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). This variant has been observed in individual(s) with G6PD deficiency (PMID: 3565372). This variant is not present in population databases (ExAC no frequency). This sequence change replaces arginine with glycine at codon 257 of the G6PD protein (p.Arg257Gly). The arginine residue is highly conserved and there is a moderate physicochemical difference between arginine and glycine. This variant disrupts the p.Arg257Met amino acid residue in G6PD. Other variant(s) that disrupt this residue have been observed in individuals with G6PD-related conditions (PMID: 20085579, 12850494), which suggests that this may be a clinically significant amino acid residue. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Dunham Lab, University of Washington RCV001348562 SCV002599227 likely pathogenic Anemia, nonspherocytic hemolytic, due to G6PD deficiency 2022-08-12 criteria provided, single submitter curation Variant found in hemizygous brothers with G6PD deficiency and CNSHA (PP4). Decreased activity in red blood cells (6-10%) (PS3). Heterozygous mother also has decreased G6PD activity (PP1). Not found in gnomAD (PM2). Post_P 0.975 (odds of pathogenicity 350.3, Prior_P 0.1).

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.